Improving cancer immunotherapies: Developing a novel antibody to CXCR2

“DJS抗体公司有一项新技术，可以让我们发现针对以前难治性疾病目标的抗体疗法。我们正在利用这项技术开发一种治疗结直肠癌和胰腺癌的新药。特别是，我们的抗体将与最近开发的激活患者免疫系统来对抗肿瘤的疗法一起发挥作用。英国每年有超过16000人死于结直肠癌，因此迫切需要发现新的治疗方法，而这个项目直接满足了这一需求。该项目详细介绍了获得临床前概念验证所需的工作，并表明针对我们目标的抗体可以减少动物癌症模型中的肿瘤生长。为了做到这一点，我们必须同时开发我们的先导抗体和一种与模型物种的免疫系统特异性相互作用的替代抗体。在未来的24个月里，我们将开发和测试这些抗体，直接促进我们先导药物的整体开发。这项工作的成果将是一流的治疗候选药物，Innovate UK的支持将加速其临床进展，并对患者的生活产生积极影响。”

"DJS Antibodies has a novel technology which allows us to discover antibody therapeutics against previously intractable disease targets. We are utilising this technology to develop a new drug to treat colorectal and pancreatic cancers. In particular, our antibody will act alongside recently developed therapies which activate patients' immune systems to fight tumours. With over 16,000 deaths each year in the UK from colorectal cancer alone, there is a real need for the discovery of novel therapies, and this project directly addresses that need.The project details the work required to attain pre-clinical proof-of-concept, and show that an antibody against our target can reduce tumour growth in animal cancer models. To do this we must develop in parallel both our lead antibody, and a surrogate antibody which interacts specifically with model species' immune system.Over 24 months we will develop and test these antibodies directly contributing to the overall development of our lead drug. The output of the work will be a best-in-class therapeutic candidate and Innovate UK's support will expedite its progression toward the clinic and to having a positive impact on patients' lives."